Tyra Biosciences, Inc. (TYRA) Dividend History

Company News

• BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight

  BALVERSA (erdafitinib), a targeted therapy for FGFR-altered urothelial carcinoma, has strong market potential as precision oncology gains emphasis. Its uptake is expected to increase, especially if expanded to earlier treatment lines or additional FGFR-driven tumors.

  GlobeNewswire Inc.

  Featured Companies: JNJ PFE URGN
• Tyra Biosciences hits 52-week high, reaching $21.67 By Investing.com - Investing.com Australia

  Tyra Biosciences, a leading biotechnology company, has reached a new 52-week high of $21.67, reflecting its robust performance and investor confidence. The company has made progress in the development of its therapeutic candidate TYRA-300 for hypochondroplasia, with positive preclinical data presented at a research conference.

  Investing.com
• Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?

  Tyra Biosciences (TYRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• S&P 500 Gains Over 1%; Amazon Earnings Top Expectations

  U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.8% on Friday. The Dow traded up 0.49% to 38,705.29 while the NASDAQ rose 1.81% to 15,639.81. The S&P 500 also rose, gaining, 1.20% to 4,965.03. Check This Out: Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday   Leading and Lagging Sectors   Communication services shares rose by 4.1% on Friday. In trading on Friday, real estate shares fell by 1.9%.   Top Headline   Amazon.com, Inc. (NASDAQ: AMZN) posted stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue to be between $138 billion and $143.5 billion versus estimates of $142.13 billion. Operating income is expected to be between $8 billion and $12 billion in the first quarter.   Equities Trading UP   Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares shot up 101% to $4.84. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million. Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) got a boost, surging 24% to $16.19. Tyra ...

  Benzinga

  Featured Companies: AMZN CING GRI INBS META TEAM